All opinions expressed by me are for entertainment purposes. Do your own due diligence and never make decisions on my expressed opinions.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Giddy up....
$16.00 TARGET
https://www.marketwatch.com/story/stifel-cuts-covid-19-vaccine-developer-inovios-price-target-as-earnings-and-call-leave-more-questions-than-answers-2020-08-11
THERE’S MONEY TO BE MADE HERE BOYS AND GIRLS....
-23%!!!!!!
Ouch!!!
10 million shares dumped at the open...
You.Were.Warned.
Inovio Pharmaceuticals sheds 12% after earnings miss, update on its COVID-19 vaccine (INO)
“The company also said its COVID-19 vaccine candidate will begin phase 2/3 clinical trials in the US in September, not over the summer as it had previously announced”.
https://markets.businessinsider.com/news/stocks/inovio-stock-price-earnings-miss-coronavirus-vaccine-update-phase-pharmaceuticals-2020-8-1029491587
Well... you just lost 12% bud
When this Russian thing gets disseminated into the news over the next day it’s gonna get ugleeeee....
You must be long on this turd...lol...
Stifel cuts COVID-19 vaccine developer Inovio's price target as earnings and call leave more questions than answers
https://www.marketwatch.com/story/stifel-cuts-covid-19-vaccine-developer-inovios-price-target-as-earnings-and-call-leave-more-questions-than-answers-2020-08-11
Stifel analysts cut their stock price target for Inovio Pharmaceuticals Inc. INO, -6.08% to $16 from $24 on Tuesday, after the company posted a wider-than-expected second-quarter loss and revenue that fell short of estimates. Inovio is one of many companies working to develop a COVID-19 vaccine candidate. The numbers and the call "left us (again) with more questions than answers on numerous fronts," analysts led by Stephen Willey wrote in a note to clients. These include disclosure timelines for the trial of the company's COVID-19 vaccine candidate, INO-4800. The company said it expanded a 40-patient early-stage clinical trial by another 80 participants and that most patients were showing an immunological response to the vaccine, either by achieving binding antibodies, neutralizing antibodies or T cell responses. "Our hesitancy to attribute any INO-4800-related value in our model persists and our previously reduced discount rate (9%) reflected improved perception re: the likelihood of procuring third party funding," said the note. "We believe these lingering questions, coupled with an acceleration of the competitive development landscape (and difficult-to-beat immunogenicity hurdles), forces us to revisit that assumption (+250bps)." The company reported a second-quarter loss of $128.7 million, or 83 cents a share, compared with a loss of $29.4 million, or 30 cents a share, in the year-ago period. Revenue rose to about $267,000 from about $136,000 in the year-ago quarter. Analysts surveyed by FactSet had forecast a loss of 17 cents a share on revenue of $2.6 million. Shares were down 8% in premarket trade Tuesday, but have gained 475% in the year to date, while the S&P 500 SPX, +0.27% has gained 4%.
Yo AMG... Where’d you go?
What’s good boys?
Did ol Kal retire yet? Took the money and ran?
Russia registers virus vaccine
“Russia on Tuesday became the first country to clear a coronavirus vaccine and declare it ready for use, despite international skepticism. President Vladimir Putin said that one of his daughters has already been inoculated”.
https://www.ctvnews.ca/health/coronavirus/russia-registers-virus-vaccine-putin-s-daughter-given-it-1.5059182
Uh oh.......................
PREMARKET DOWN 12%
Shorty short shorts are crushing it! Whoooooo....... $4.00 here we come!!!!!!
I warned you fools.........
On our way to $17
You.Were.Warned.
Hello $18s..... here we goooo..
The shares were sold on the public market..lol. I've proved that already
I warned you guys... the botttom is dropping out of this turd as I type
You.Were.Warned.
INOVIO PRESIDENT/CEO JOSEPH KIM DUMPS 100,000 shares @$21.13
http://d18rn0p25nwr6d.cloudfront.net/CIK-0001055726/c9c63b06-0697-495b-9f05-b3f02ab90295.pdf
Coincidence the CEO is dumping shares and then a storm of bad PRs? I think not....
INOVIO PRESIDENT/CEO JOSEPH KIM DUMPS 100,000 shares @$21.13
http://d18rn0p25nwr6d.cloudfront.net/CIK-0001055726/c9c63b06-0697-495b-9f05-b3f02ab90295.pdf
Three reasons to sell INOVIO stock
https://investorplace.com/2020/07/3-reasons-to-sell-ino-stock/
The bad PR train has left the station.
Expect more... I warned you guys
SHOULD BE AN INTERESTING WEEK...
INOVIO PRESIDENT/CEO JOSEPH KIM DUMPS 100,000 shares @$21.13
http://d18rn0p25nwr6d.cloudfront.net/CIK-0001055726/c9c63b06-0697-495b-9f05-b3f02ab90295.pdf
Your posts reek of panic....lol!!!!
the shares were liquidated on the open market and I have provided proof
INOVIO PRESIDENT/CEO JOSEPH KIM DUMPS 100,000 shares @$21.13
http://d18rn0p25nwr6d.cloudfront.net/CIK-0001055726/c9c63b06-0697-495b-9f05-b3f02ab90295.pdf
DOWNNNNNN.......
Be ready for it. Short attack!!!
They were sold on the open market..lol!!!
Filings by transaction date
Jul 30, 2020 (filed on Jul 31, 2020)
Insider Name:Kim Jong Joseph
Ownership Type:Direct Ownership
Securities:Common Stock
Nature of Transaction:S - Open market
# or value acquired/disposed of:-100,000
Price:$21.13
Spin it buddy....spin it any way you want
He sold 100,000 of his personal shares!
$2,133,000 worth!
Read the form. The shares were disposed.
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
Amount
(A) or (D)
Price
100000
D
$21.1345
This turd will be shorted back to $4...
Do the math. They were sold on the open market. The family owned shares were only declared on the form as they were indirectly owned.
He sold almost 10% of his holdings!
$2,113,000 worth of shares!
"Rookie"....lol. Seems you can't even read a Form 4 correctly..lol!!!
BLOODBATH NEXT WEEK.....
INOVIO PRESIDENT/CEO JOSEPH KIM DUMPS 100,000 shares @$21.13
http://d18rn0p25nwr6d.cloudfront.net/CIK-0001055726/c9c63b06-0697-495b-9f05-b3f02ab90295.pdf
It’s going to be a bloodbath next week...
That was fun and profitable. See you next time Champions!
Looking good.... +15%
WHO’S READY TO PARTY!?!?
Cannabix Technologies Files Patent for Detection of Molecules in Breath using High-field asymmetric waveform ion mobility spectrometry (FAIMS)
For immediate release. Vancouver, British Columbia, July 6, 2020: Cannabix Technologies Inc.(CSE: BLO, OTC PINK: BLOZF) (the “Company”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) entitled, “Apparatus and Methods for Detection of Molecules”. This provisional patent covers multiple new inventions and intellectual property (“IP”) related the development to the Company’s FAIMS (field asymmetric waveform ion mobility spectrometry) based marijuana breathalyzer technology. This new patent application is the culmination of research and development work conducted by Cannabix scientists and engineers in the areas of ion mobility spectrometry, fluid dynamics, and non-volatile molecule sampling, during which several significant technical challenges have been overcome. This patent application seeks protection for, among others, novel methods in asymmetric waveform generation and application and ion optics design. It is anticipated that additional IP will be included in the subsequent non-provisional patent filing and that these techniques can lead to utility in other areas related to detection of molecules in breath.
Cannabix is using its FAIMS system to isolate and detect ?9-tetrahydrocannabinol (“THC”), a non-volatile compound, in breath. The Cannabix device has been designed and built in a series of modules that together allow for sample intake, ionization, ion focusing and direction, filtering and detection – all done under atmospheric pressure. This modular design provides the flexibility for the potential detection of other molecules of interest in breath. In addition, the device has the ability to couple directly to a mass spectrometer in order to validate its detector responses.
The Company reported results of field testing earlier this year such that its FAIMS device is capable of selectively isolating and detecting THC from human breath up to 90 min after subjects consumed both marijuana and nicotine. Further improvements have been made since then and engineers are well into the next iteration of design.
“Cannabix has developed a unique system with several non-obvious features that have been discovered through our commitment to research and development and innovation. The breath is composed of both volatile and non-volatile components --volatile components like alcohol are relatively easy to detect. The detection of non-volatile compounds like THC under atmospheric pressure (without vacuum) in a humid environment is not an easy endeavour and we believe our work will lead to new types of devices that the analytical and diagnostic fields have been seeking for breath analysis, and possibly other applications. Furthermore, this provisional patent should open the door to several additional patent opportunities.” stated Dr. Raj Attariwala, Chief Scientific Officer.
Once bitten, twice shy
Slow slide from this level. Big news has come and gone.
Next resistance looks like $14
It's nice to see people can admit to their mistakes...
SEC COMPLAINT FORM
I urge concerned investors to take the time to register a complaint with the SEC for a full investigation. Be sure to follow up the complaint for further class action lawsuits if required.
https://www.sec.gov/oiea/Complaint.html
How does this company get away with this crap...
I urge shareholders to contact the SEC for a full investigation.
What a turd...
The worst part is this will take a week to settle back to the bottom without any real news on the horizon
It will.......
"The company suffered a setback last week when a Montgomery County Common Pleas Court judge rejected Inovio’s move to force its contract manufacturer to share proprietary technology with other suppliers.
Inovio argued that Houston-based VGXI is already at manufacturing capacity and is an obstacle to Inovio’s goal of being able to make one million doses of its vaccine by year’s end. Judge Jeffrey Saltz denied Inovio’s petition for a preliminary injunction, concluding that the claims are “too speculative.”"
Pre-market is down 12.06%
Exactly where are you deriving this "buy and sell" data from?
Your vernacular gives away your ignorance...